Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: Potential biomarkers for a more favorable prognosis?

References

• Abdel-Wahab, M., Mostafa, M., Sabry, M., et al. 2008. Aflatoxins as a risk factor for hepatocellular carcinoma in Egypt: Mansoura Gastroenterology Center study. Hepatogastroenterology 55:1754–1759
   PubMed Web of Science ®Google Scholar
• Abu Mouch, S., Fireman, Z., Jarchovsky, J., and Assy, N. 2010. Vitamin D supplement improve SVR in chronic hepatitis C (genotype I) naive patients treated with PEG, interferon, and ribavirin. 45th Annual Meeting of European Association for Study of the Liver (EASL 2010). Vienna, Austria
   Google Scholar
• Abu Mouch, S., Fireman, Z., Jarchovsky, J., et al. 2011. Vitamin D supplement improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J. Gastroenterol. 17:5184–5190
   PubMed Web of Science ®Google Scholar
• Ataseven, H., Bahcecioglu, I. H., Kuzu, N., et al. 2006. The levels of ghrelin, leptin. TNFα, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediat. Inflamm. 4:78380
   Google Scholar
• Babbs, C., Smith, A., Hunt, L. P., et al. 1988. Type III pro-collagen peptide: A marker activity and prognosis in primary biliary cirrhosis. Lancet 1:1021–1024
   PubMed Web of Science ®Google Scholar
• Bertino, G., Neri, S., Bruno, C. M., et al. 2011. Diagnostic and prognostic value of α-fetoprotein, des-γ-carboxy-prothrombin, and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med. 102:363–371
   PubMedGoogle Scholar
• Bialecki, E. S., and Di Bisceglie, A. M. 2005. Clinical presentation and natural course of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 17:485–489
   PubMed Web of Science ®Google Scholar
• Caldwell, C. C., Okaya, T., Martignoni, A., et al. 2005. Divergent functions of CD4 T-lymphocytes in acute liver inflammation and injury after ischemia-reperfusion. Am. J. Physiol. 289:G969–976
   Google Scholar
• Chan, S. L., Mo, F. K., Wong, C. S., et al. 2012. A study of circulating IL-10 in prognostication of un-resectable hepatocellular carcinoma. Cancer 118:3984–3992
   PubMed Web of Science ®Google Scholar
• Colin, E. M., Asmawidjaja, P. S., van Hamburg, J. P., et al. 2010. 1,25-dihydroxyvitamin D3 modulates TH17 polarization and IL-22 expression by memory T-cells from patients with early rheumatoid arthritis. Arthritis Rheum. 62:132–142
   PubMed Web of Science ®Google Scholar
• Deluca, H. F., and Cantorna, M. T. 2001. Vitamin D: Its role and uses in immunology. FASEB J. 15:2579–2585
   PubMed Web of Science ®Google Scholar
• Denning, T. L., Wang, Y. C., Patel, S. R., et al. 2007. Lamina propria macrophages and dendritic cells differentially induce regulatory and IL-17-producing T-cell responses. Nat. Immunol. 8:1086–1094
   PubMed Web of Science ®Google Scholar
• Durazo, F. A., Blatt, L. M., Corey, W. G., et al. 2008. Des-γ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 23:1541–1548
   PubMed Web of Science ®Google Scholar
• El-Houseini, M. E., Mohammed, M. S., Elshemey, W. M., et al. 2005. Enhanced detection of hepatocellular carcinoma. Cancer Control 12:248–253
   PubMedGoogle Scholar
• El Husseiny, N. M., Fahmy, H. M., Mohamed, W. A., and Amin, H. H. 2012. Relationship between vitamin D and IL-23, IL-17, and MCP-1 as markers of fibrosis in hepatitis C+ Egyptians. World J. Hepatol. 4:242–247
   PubMedGoogle Scholar
• Elnemr, D. M., Abdel-Azeez, H. A., Labib, H. A., and Abo-Taleb, F. M. 2012. Clinical relevance of serum endoglin level in Egyptian hepatocellular carcinoma patients. Clin. Lab. 58:1023–1028
   PubMedGoogle Scholar
• Elsharkawy, A. M., and Mann, D. A. 2007. Nuclear factor-κB and the hepatic inflammation- fibrosis-cancer axis. Hepatology 46:590–597
   PubMed Web of Science ®Google Scholar
• Falasca, K., Ucciferri, C., Dalessandro, M., et al. 2006. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann. Clin. Lab. Sci. 36:144–150
   PubMed Web of Science ®Google Scholar
• Fathy, A., Ahmed, A. S., Metwally, L., and Hassan, A. 2011. T-Helper Type 1/T-helper Type 17-related cytokines in chronic Hepatitis C patients before and after interferon and ribavirin therapy. Med. Princ. Pract. 20:345–349
   PubMedGoogle Scholar
• Fisher, L., and Fisher, A. 2007. Vitamin D and parathyroid hormone in outpatients with non-cholestatic chronic liver disease. Clin. Gastroenterol. Hepatol. 5:513–520
   PubMed Web of Science ®Google Scholar
• Giardina, M. G., Matarazzo, M., Varriale, A., et al. 1992. Serum α-L-fucosidase. A useful marker in the diagnosis of hepatocellular carcinoma. Cancer 70:1044–1048
   PubMedGoogle Scholar
• Heninger, E., Hogan, L. H., Karman, J., et al. 2006. Characterization of the Histoplasma capsulatum-induced granuloma. J. Immunol. 177:3303–3313
   PubMed Web of Science ®Google Scholar
• Holick, M. F., and Chen, T. C. 2008. Vitamin D deficiency: A worldwide problem with health consequences. Am. J. Clin. Nutr. 87:1080S–1086S
   PubMed Web of Science ®Google Scholar
• Hollis, B. W. 1986. Assay of circulating 1,25-dihydroxy Vitamin D involving a novel single-cartridge extraction and purification procedure. Clin. Chem. 32:2060–2063
   PubMed Web of Science ®Google Scholar
• Hsia, C. Y., Huo, T. I., Chiang, S. Y., et al. 2007. Evaluation of IL-6, IL-10, and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur. J. Surg. Oncol. 33:208–212
   PubMed Web of Science ®Google Scholar
• Jimenez-Sousa, M. A., Almansa, R., de la Fuente, C., et al. 2010. Increased TH1, TH17, and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin. Eur. Cytokine Network 21:84–91
   PubMedGoogle Scholar
• Johnson, P. J. 2001. The role of serum α-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin. Liver Dis. 5:145–159
   PubMedGoogle Scholar
• Kamal, S. M., and Nasser, I. A. 2008. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology 47:1371–1383
   PubMed Web of Science ®Google Scholar
• Korn, T., Bettelli, E., Oukka, M., and Kuchroo, V. K. 2009. IL-17 and TH17 cells. Annu. Rev. Immunol. 27:485–517
   PubMed Web of Science ®Google Scholar
• Krstić, G. 2010. TH17 mediators and vitamin D status. Crit. Care 14:410
   PubMedGoogle Scholar
• Lange, C. M., Bojunga, J., Ramos-Lopez, E., et al. 2011. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to IFNα-based therapy. J. Hepatol. 54:887–893
   PubMed Web of Science ®Google Scholar
• Lange, N. E., Litonjua, A., Hawrylowicz, C. M., and Weiss, S. 2009. Vitamin D, the immune system, and asthma. Expert Rev. Clin. Immunol. 5:693–702
   PubMed Web of Science ®Google Scholar
• Lee, Y., Park, U. S., Choi, I., et al. 1998. Human IL-6 gene is activated by hepatitis B virus-X protein in human hepatoma cells. Clin. Cancer Res. 4:1711–1717
   PubMed Web of Science ®Google Scholar
• Lehman, E. M., and Wilson, M. L. 2009. Epidemic hepatitis C virus infection in Egypt: Estimates of past incidence and future morbidity and mortality. J. Viral Hepat. 16:650–658
   PubMed Web of Science ®Google Scholar
• Lemmers, A., Moreno, C., Gustot, T., et al. 2009. The IL-17 pathway is involved in human alcoholic liver disease. Hepatology 49:646–657
   PubMed Web of Science ®Google Scholar
• Mahon, B. D., Wittke, A., Weaver, V., and Cantorna, M. T. 2003. Targets of vitamin D depend on differentiation and activation status of CD4+ T-cells. J. Cell. Biochem. 89:922–932
   PubMed Web of Science ®Google Scholar
• Mawer, E. B. 1980. Clinical implications of measurements of circulating vitamin D metabolites. Clin. Endocrinol. Metab. 9:63–79
   PubMedGoogle Scholar
• Mohran, Z. Y., Ali-Eldin, F. A., and Abdel Aal, H. A. 2011. Serum IL-18: Does it have a role in diagnosis of hepatitis C virus-related hepatocellular carcinoma? Arab J. Gastroenterol. 12:29–33
   Google Scholar
• Muller, K., Svenson, M., and Bendtzen, K. 1988. 1α,25-Dihydroxyvitamin D3 and a novel vitamin D analogue MC903 are potent inhibitors of human IL-1 in vitro. Immunol. Lett. 17:361–365
   PubMed Web of Science ®Google Scholar
• Petta, S., Cammà, C., Scazzone, C., et al. 2010. Low Vitamin D serum level is related to severe fibrosis and low responsiveness to IFN-based therapy in genotype I chronic hepatitis C. Hepatology 51:1158–1167
   PubMed Web of Science ®Google Scholar
• Porta, C., De Amici, M., Quaglini, S., et al. 2008. Circulating IL-6 as a tumor marker for hepatocellular carcinoma. Ann. Oncol. 19:353–358
   PubMed Web of Science ®Google Scholar
• Rutitzky, L. I., Bazzone, L., Shainheit, M. G., et al. 2008. IL-23 is required for the development of severe egg-induced immunopathology in schistosomiasis and for lesional expression of IL-17. J. Immunol. 180:2486–2495
   PubMed Web of Science ®Google Scholar
• Schaalan, M. F., Mohamed, W. A., and Amin, H. H. 2012. Vitamin D deficiency: Correlation to IL-17, IL-23, and PIIINP in hepatitis C virus genotype 420. World J. Gastroenterol. 18:3738–3744
   PubMedGoogle Scholar
• Scott, J. D., and Gretch, D. R. 2007. Molecular diagnostics of hepatitis C virus infection: A systematic review. JAMA 297:724–732
   PubMed Web of Science ®Google Scholar
• Shimizu, A., Shiraki, K., Ito, T., et al. 2002. Sequential fluctuation pattern of serum des-γ-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis. Int. J. Mol. Med. 9:245–250
   PubMed Web of Science ®Google Scholar
• Shirakawa, A. K., Nagakubo, D., Hieshima, K., et al. 2008. 1,25-dihydroxyvitamin D3 induces CCR10 expression in terminally differentiating human B-cells. J. Immunol. 180:2786–2795
   PubMed Web of Science ®Google Scholar
• Soliman, A. S., Hung, C. W., Tsodikov, A., et al. 2010. Epidemiologic risk factors of hepatocellular carcinoma in a rural region of Egypt. Hepatol. Int. 4:681–690
   PubMedGoogle Scholar
• Soresi, M., Giannitrapani, L., D'Antona, F., et al. 2006. IL-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J. Gastroenterol. 12:2563–2568
   PubMedGoogle Scholar
• Spadaro, A., Ajello, A., Luigiano, C., et al. 2006. Low utility of plasma nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 12:4716–4720
   PubMedGoogle Scholar
• Steib, C. J., Gerbes, A. L., Bystron, M., et al. 2007. Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A2. J. Hepatol. 47:228–238
   PubMed Web of Science ®Google Scholar
• Tai, W. C., Hu, T. H., Wang, J. H., et al. 2009. Clinical implications of α-fetoprotein in chronic hepatitis C. J. Formosa Med. Assoc. 108:210–218
   PubMed Web of Science ®Google Scholar
• Wang, L., Chen, S., and Xu, K. 2011. IL-17 expression is correlated with hepatitis B-related liver diseases and fibrosis. Int. J. Mol. Med. 27:385–392
   PubMedGoogle Scholar
• Wang, W. W., Wang, Z. M., Liu, Y. Y., et al. 2010. Increased level of TH17 cells in peripheral blood correlates with the development of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi. 32:757–761
   PubMedGoogle Scholar
• Weaver, C. T., Hatton, R. D., Mangan, P. R., and Harrington, L. E. 2007. IL-17 family cytokines and the expanding diversity of effector T-cell lineages. Annu. Rev. Immunol. 25:821–852
   PubMed Web of Science ®Google Scholar
• Welling, T. H., Fu, S., Wan, S., et al. 2012. Elevated serum IL-8 is associated with presence of hepatocellular carcinoma and independently predicts survival. Cancer Invest. 30:689–697
   PubMed Web of Science ®Google Scholar
• Yasumi, Y., Takikawa, Y., Endo, R., and Suzuki, K. 2007. Interleukin-17 as a new marker of severity of acute hepatic injury. Hepatol. Res. 37:248–254
   PubMedGoogle Scholar
• Yen, D., Cheung, J., Scheerens, H., et al. 2006. IL-23 is essential for T-cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116:1310–1316
   PubMed Web of Science ®Google Scholar
• Zhang, J. P., Yan, J., Xu, J., et al. 2009. Increased intra-tumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 50:980–989
   PubMed Web of Science ®Google Scholar
• Zhang, J. Y., Zhang, Z., Lin, F., et al. 2010. IL-17-producing CD4+ T-cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 51:81–91
   PubMed Web of Science ®Google Scholar
• Zhao, L., Tang, Y., You, Z., et al. 2011. IL-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic IL-6 expression. PLoS One 6:e18909
   PubMed Web of Science ®Google Scholar
• Zhou, L., Liu, J., and Luo, F. 2006. Serum tumor markers for detection of hepatocellular carcinoma. World J. Gastroenterol. 12:1175–1181
   PubMed Web of Science ®Google Scholar